PROCEPT BioRobotics Posts 19% Revenue Growth in Q2, Lifts Procedure Guidance
PRCT is trading near its 52-week low of $16.665 (5.4% above the low) on elevated volume (2.3× avg).
Summary
PROCEPT BioRobotics reported Q2 2026 revenue of $94.5 million, up 19% year-over-year, and raised its full-year procedure volume guidance. Net loss widened to $26.9 million, while the full-year revenue outlook of $390–$410 million was reiterated.
Key Events · Earnings and Guidance · PRCT
-
Q2 Revenue Beats Expectations
Revenue of $94.5 million grew 19% year-over-year, driven by 21% U.S. procedure growth and a record 65 HYDROS system placements.
-
Procedure Guidance Raised
Full-year 2026 U.S. procedure volume guidance increased to 54,000–56,000, up from the prior implied range, reflecting strong demand.
-
Net Loss Widens
Net loss expanded to $26.9 million from $19.6 million in Q2 2025, as operating expenses rose 21% to $89.8 million.
-
Adjusted EBITDA Loss Improves
Full-year adjusted EBITDA loss guidance narrowed to $35–$30 million, better than prior expectations, signaling progress toward breakeven.
Analysis · PRCT · Industrial Applications And Services
A solid quarter saw revenue climb 19% to $94.5 million, fueled by record HYDROS system placements and higher handpiece pricing. Confidence in demand is underscored by the raised full-year U.S. procedure volume guidance, now at 54,000–56,000. Yet the net loss widened to $26.9 million from $19.6 million a year ago as operating expenses grew 21%, and cash burn persists. The reiterated revenue guidance of $390–$410 million and an improved adjusted EBITDA loss outlook paint a mixed picture: growth remains intact, but profitability is still elusive. Adding a legal overhang, this earnings report arrives just one day after a securities fraud class action lawsuit was filed against the company.
At the time of this filing, PRCT was trading at $17.57 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1B. The 52-week trading range was $16.67 to $51.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.